Symbicort Turbuhaler 30/60 Clinical Experience Investigation

The purpose of this study is to confirm the safety (ADR related to beta stimulant drugs, unexpected ADRs) and efficacy of Symbicort in daily practice and the control status on bronchial asthma and Patient satisfaction

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bronchial Asthma Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Okazaki, Aichi-ken, Japan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients treated with Symbicort for the first time due to bronchial asthma

Exclusion criteria

Treatment and study plan

Primary outcomes

Incidence of Adverse Events

Time frame: Range of 12 weeks

Secondary outcomes

The level of asthma control

Time frame: Range of 12 weeks
The level of patient satisfaction with Symbicort

Time frame: Range of 12 weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: SURE

Important dates

Study start: 2010
Primary completion: 2011
Study completion: 2011
First posted: Nov 2, 2010
Registry last updated: Dec 7, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed